Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Issue 1 (28th August 2018)

• Record Type: Journal Article
• Authors: Lieberman, Nicole A P; DeGolier, Kole; Kovar, Heather M; Davis, Amira; Hoglund, Virginia; Stevens, Jeffrey; Winter, Conrad; Deutsch, Gail; Furlan, Scott N; Vitanza, Nicholas A; Leary, Sarah E S; Crane, Courtney A
• Is Part Of: Neuro-oncology. Volume 21:Issue 1(2019)
• Page Start: 83
• Page End: 94
• Publication Date: 2018-08-28
• Subjects: DIPG -- tumor microenvironment -- immunotherapy -- tumor-associated macrophage -- NK cell; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noy145
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Background: Diffuse intrinsic pontine glioma (DIPG) is a uniformly fatal CNS tumor diagnosed in 300 American children per year. Radiation is the only effective treatment and extends overall survival to a median of 11 months. Due to its location in the brainstem, DIPG cannot be surgically resected. Immunotherapy has the ability to target tumor cells specifically; however, little is known about the tumor microenvironment in DIPGs. We sought to characterize infiltrating immune cells and immunosuppressive factor expression in pediatric low- and high-grade gliomas and DIPG. Methods: Tumor microarrays were stained for infiltrating immune cells. RNA was isolated from snap-frozen tumor tissue and Nanostring analysis performed. DIPG and glioblastoma cells were co-cultured with healthy donor macrophages, T cells, or natural killer (NK) cells, and flow cytometry and cytotoxicity assays performed to characterize the phenotype and function, respectively, of the immune cells. Results: DIPG tumors do not have increased macrophage or T-cell infiltration relative to nontumor control, nor do they overexpress immunosuppressive factors such as programmed death ligand 1 and/or transforming growth factor β1. H3.3-K27M DIPG cells do not repolarize macrophages, but are not effectively targeted by activated allogeneic T cells. NK cells lysed all DIPG cultures. Conclusions: DIPG tumors have neither a highly immunosuppressive nor inflammatory microenvironment. Therefore, major considerations for the development of immunotherapy will be the recruitment, activation, and retention of tumor-specific effector immune cells.